文献速递血栓与止血

溶栓治疗静脉血栓栓塞事件:系统综述与荟萃分析

Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis.
PubMed 文献 · Blood Adv · 2020-01-01

该系统综述纳入45项随机对照试验共4740例静脉血栓栓塞患者,评估溶栓治疗的有效性与安全性。结果显示溶栓可能降低肺栓塞死亡率(RR 0.61)并减少血栓后综合征(RR 0.70),但显著增加大出血(RR 1.89)和颅内出血(RR 3.17)风险。

要点

  • 溶栓可能降低次大面积或中危肺栓塞患者死亡率(RR 0.61,95%CI 0.40-0.94)。
  • 溶栓可能减少近端深静脉血栓患者的血栓后综合征(RR 0.70,95%CI 0.59-0.83)。
  • 溶栓显著增加大出血(RR 1.89)和颅内出血(RR 3.17)风险。

核心结论

  • 溶栓可能降低次大面积或中危肺栓塞患者死亡率,并可能减少近端深静脉血栓患者的血栓后综合征,但以显著增加大出血为代价。

研究设计与样本

  • 系统综述与荟萃分析,检索Medline、Embase和Cochrane数据库至2019年2月的随机对照试验,纳入45项研究共4740例肺栓塞和/或深静脉血栓患者。

主要发现

  • 肺栓塞研究中,溶栓可能降低死亡率(RR 0.61;95%CI 0.40-0.94;中等确定性)并可能减少非致命性肺栓塞复发(RR 0.56;95%CI 0.35-0.89;低确定性)。
  • 深静脉血栓研究中,溶栓可能对死亡率(RR 0.77;95%CI 0.26-2.28;低确定性)和深静脉血栓复发(RR 0.99;95%CI 0.56-1.76;低确定性)无影响,但可能减少血栓后综合征(RR 0.70;95%CI 0.59-0.83;低确定性)。
  • 全部证据合并分析显示,溶栓增加大出血(RR 1.89;95%CI 1.46-2.46;高确定性)并可能增加颅内出血(RR 3.17;95%CI 1.19-8.41;中等确定性)。

关键数值与推荐

  • 肺栓塞溶栓死亡风险比RR 0.61(95%CI 0.40-0.94),非致命性复发RR 0.56(95%CI 0.35-0.89)。
  • 深静脉血栓溶栓血栓后综合征风险比RR 0.70(95%CI 0.59-0.83),死亡率RR 0.77(95%CI 0.26-2.28),复发RR 0.99(95%CI 0.56-1.76)。
  • 大出血风险比RR 1.89(95%CI 1.46-2.46),颅内出血RR 3.17(95%CI 1.19-8.41)。

临床怎么用

  • 临床决策需权衡溶栓获益与出血风险,基线风险深刻影响净获益,应个体化选择可能受益的患者。

局限性

  • 证据确定性受限于部分结局为低确定性,且获益与风险的平衡受基线风险影响显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombolytic therapy might reduce venous thromboembolism-related mortality and morbidity, but it could also increase the risk of major bleeding. We systematically reviewed the literature to evaluate the effectiveness and safety of thrombolytics in patients with pulmonary embolism (PE) and/or deep venous thrombosis (DVT). We searched Medline, Embase, and Cochrane databases for relevant randomized controlled trials up to February 2019. Multiple investigators independently screened and collected data. We included 45 studies (4740 participants). Pooled estimates of PE studies indicate probable reduction in mortality with thrombolysis (risk ratio [RR], 0.61; 95% confidence interval [CI], 0.40-0.94) (moderate certainty) and possible reduction in nonfatal PE recurrence (RR, 0.56; 95% CI, 0.35-0.89) (low certainty). Pooled estimates of DVT studies indicate the possible absence of effects on mortality (RR, 0.77; 95% CI, 0.26-2.28) (low certainty) and recurrent DVT (RR, 0.99; 95% CI, 0.56-1.76) (low certainty), but possible reduction in postthrombotic syndrome (PTS) with thrombolytics (RR, 0.70; 95% CI, 0.59-0.83) (low certainty). Pooled estimates of the complete body of evidence indicate increases in major bleeding (RR, 1.89; 95% CI, 1.46-2.46) (high certainty) and a probable increase in intracranial bleeding (RR, 3.17; 95% CI 1.19-8.41) (moderate certainty) with thrombolytics. Our findings indicate that thrombolytics probably reduce mortality in patients with submassive- or intermediate-risk PE and may reduce PTS in patients with proximal DVT at the expense of a significant increase in major bleeding. Because the balance between benefits and harms is profoundly influenced by the baseline risks of critical outcomes, stakeholders involved in decision making would need to weigh these effects to define which clinical scenarios merit the use of thrombolytics.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Izcovich A, Criniti JM, Popoff F, et al. Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis. Blood Adv. 2020. PMID: 32289164. doi:10.1182/bloodadvances.2020001513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。